Global Epidemiology of Tuberculosis

Abstract

With 1.4 million deaths in 2011 and 8.7 million new cases, tuberculosis (TB) disease remains a global scourge. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. Achieving these targets is the focus of national and international efforts in TB control, and demonstrating whether or not they are achieved is of major importance to guide future and sustainable investments.

This paper discusses the methods used to estimate the global burden of TB; estimates of incidence, prevalence, and mortality for 2011, combined with assessment of progress toward the 2015 targets for reductions in these indicators based on trends since 1990 and projections up to 2015; trends in TB notifications and in the implementation of the Stop TB Strategy; and prospects for elimination of TB by 2050.

Keywords

tuberculosis - epidemiology - burden - incidence - prevalence - mortality

• References

• 1 WHO. Global tuberculosis report 2012. Geneva, Switzerland: WHO; 2012
• 2 WHO, ed. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008
• 3 Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367 (9524) 1747-1757
• 4 Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE 2009; 4 (4) e5080
• 5 Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. Reflections on the white plague. Lancet Infect Dis 2009; 9 (3) 197-202
• 6 Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012; 10 (6) 407-416
• 7 Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338 (8778) 1305-1308
• 8 Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman JG, Measham AR, , et al, eds. Disease Control Priorities in Developing Countries. Washington, DC: Oxford University Press; 2006: 289-309
• 9 Dye C, Bassili A, Bierrenbach AL , et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8 (4) 233-243
• 10 Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367 (9514) 952-955
• 11 Korenromp EL, Glaziou P, Fitzpatrick C , et al. Implementing the global plan to stop TB, 2011–2015—optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS ONE 2012; 7 (6) e38816
• 12 Raviglione MC. The Global Plan to Stop TB, 2006–2015. Int J Tuberc Lung Dis 2006; 10 (3) 238-239
• 13 Raviglione MC. The new Stop TB Strategy and the Global Plan to Stop TB, 2006–2015. Bull World Health Organ 2007; 85 (5) 327
• 14 Van Hest NA, Story A, Grant AD, Antoine D, Crofts JP, Watson JM. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999–2002. Epidemiol Infec 2008; 136 (12) 1606-1616
• 15 Bierrenbach AL, Stevens AP, Gomes AB , et al. [Impact on tuberculosis incidence rates of removal of repeat notification records.]. Rev Saude Publica 2007; 41 (Suppl. 01) 67-76
• 16 Dye C, Ottmani S, Laasri L, Bencheikh N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int J Tuberc Lung Dis 2007; 11 (11) 1225-1231
• 17 Mansoer JSS, Scheele S, Floyd K, Dye C, Sitienei J, Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ 2009; 87 (3) 186-192 , 192A–192B
• 18 Botha E, den Boon S, Lawrence KA , et al. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis 2008; 12 (8) 936-941
• 19 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282 (7) 677-686
• 20 Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 2001; 358 (9285) 912-916
• 21 Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 2008; 8: 72
• 22 Véron LJ, Blanc LJ, Suchi M, Raviglione MC. DOTS expansion: will we reach the 2005 targets?. Int J Tuberc Lung Dis 2004; 8 (1) 139-146
• 23 Baussano I, Bugiani M, Gregori D , et al. Undetected burden of tuberculosis in a low-prevalence area. Int J Tuberc Lung Dis 2006; 10 (4) 415-421
• 24 Borgdorff MW, Glynn JR, Vynnycky E. Using capture-recapture methods to study recent transmission of tuberculosis. Int J Epidemiol 2004; 33 (4) 905-906 , author reply 907
• 25 Cailhol J, Che D, Jarlier V, Decludt B, Robert J. Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. Int J Tuberc Lung Dis 2005; 9 (7) 803-808
• 26 Crofts JP, Pebody R, Grant A, Watson JM, Abubakar I. Estimating tuberculosis case mortality in England and Wales, 2001–2002. Int J Tuberc Lung Dis 2008; 12 (3) 308-313
• 27 WHO, ed. Tuberculosis Prevalence Surveys: A Handbook. Geneva, Switzerland: WHO; 2011
• 28 Glaziou P, van der Werf MJ, Onozaki I , et al. Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis 2008; 12 (9) 1003-1008
• 29 Soemantri S, Senewe FP, Tjandrarini DH , et al. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis 2007; 11 (4) 398-404
• 30 Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 2000; 29 (3) 558-564
• 31 Tupasi TE, Radhakrishna S, Rivera AB , et al. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis 1999; 3 (6) 471-477
• 32 Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998; 2 (1) 27-36
• 33 Korenromp EL, Bierrenbach AL, Williams BG, Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 2009; 13 (3) 283-303
• 34 WHO. Guidelines for Surveillance of Drug Resistance in Tuberculosis. Geneva, Switzerland: WHO; 2009
• 35 Riley RL. The contagiosity of tuberculosis. Schweiz Med Wochenschr 1983; 113 (3) 75-79
• 36 WHO. Tuberculosis Fact Sheet. Geneva, Switzerland: WHO; 2012
• 37 Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011; 40 (4) 964-970
• 38 Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000; 152 (3) 247-263
• 39 Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 2011; 6 (4) e17601
• 40 Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS ONE 2011; 6 (6) e20755
• 41 Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1411) 1069-1075
• 42 Glaziou P, Floyd K, Korenromp EL , et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ 2011; 89 (8) 573-582
• 43 Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE 2010; 5 (12) e15241
• 44 Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 2010; 107 (45) 19485-19489
• 45 Corbett EL, Charalambous S, Moloi VM , et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170 (6) 673-679
• 46 Ottmani SE, Uplekar MW. Gender and TB: pointers from routine records and reports. Int J Tuberc Lung Dis 2008; 12 (7) 827-828
• 47 Thorson A, Long NH, Larsson LO. Chest X-ray findings in relation to gender and symptoms: a study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis 2007; 39 (1) 33-37
• 48 Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis 2000; 4 (2) 123-132
• 49 Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q 1996; 49 (2) 115-119
• 50 Somma D, Thomas BE, Karim F , et al. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis 2008; 12 (7) 856-866
• 51 WHO. Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015. WHO Progress Report 2011. Geneva, Switzerland: WHO; 2011. . Report No.: WHO/HTM/TB/2011.3
• 52 Zignol M, van Gemert W, Falzon D , et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 2012; 90 (2) 111-119D
• 53 WHO. WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide. Geneva, Switzerland: WHO; 2006. . Available at: www.who.int/mediacentre/news/notes/2006/np29/ . Accessed January 18, 2013
• 54 Velayati AA, Masjedi MR, Farnia P , et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136 (2) 420-425
• 55 Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12 (5) E070517.1
• 56 Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54 (4) 579-581
• 57 WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update. Geneva, Switzerland: WHO; 2011
• 58 Meyer-Rath G, Schnippel K, Long L , et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE 2012; 7 (5) e36966
• 59 Evans CA. GeneXpert—a game-changer for tuberculosis control?. PLoS Med 2011; 8 (7) e1001064
• 60 Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352 (9144) 1886-1891
• 61 Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293 (22) 2767-2775
• 62 Lönnroth K, Castro KG, Chakaya JM , et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375 (9728) 1814-1829
• 63 Raviglione M, Marais B, Floyd K , et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379 (9829) 1902-1913
• 64 Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29 (5) 481-491
• 65 Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull World Health Organ 1993; 71 (3–4) 297-306
• 66 Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57 (4, Suppl) S1-S58
• 67 WHO. Health Financing for Universal Coverage. Geneva, Switzerland: WHO; 2012
• 68 Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008; 5 (23) 653-662
• 69 Sterling TR. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 2008; 29 (5) 532-541
• 70 Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; (1) CD000171
• 71 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl. 01) S52-S62
• 72 Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13 (1) 6-16
• 73 Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005; 19 (2) 163-168
• 74 WHO and UNAIDS issue new guidance on HIV testing and counselling in health facilities, 2007. http://www.who.int/mediacentre/news/releases/2007/pr24/en/index.html . Accessed January 12, 2013
• 75 Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196 (Suppl. 01) S108-S113
• 76 Wells CD, Cegielski JP, Nelson LJ , et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 (Suppl. 01) S86-S107
• 77 WHO, ed. Global Tuberculosis Control 2009: Surveillance, Planning, Financing. Geneva, Switzerland: WHO; 2009
• 78 Shah NS, Wright A, Bai GH , et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13 (3) 380-387
• 79 Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?. EurRespir J 2007; 29 (3) 423-427
• 80 Manissero D, Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 2006; 11 (11) E061103.1
• 81 Raviglione M. XDR-TB: entering the post-antibiotic era?. Int J Tuberc Lung Dis 2006; 10 (11) 1185-1187
• 82 Raviglione MC, Smith IM. XDR tuberculosis—implications for global public health. N Engl J Med 2007; 356 (7) 656-659
• 83 Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6 (11) 710-725
• 84 Lönnroth K, Uplekar M, Arora VK , et al. Public-private mix for DOTS implementation: what makes it work?. Bull World Health Organ 2004; 82 (8) 580-586
• 85 Ambe G, Lönnroth K, Dholakia Y , et al. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis 2005; 9 (5) 562-568
• 86 Lönnroth K, Uplekar M. Invest in breaking the barriers of public-private collaboration for improved tuberculosis care. Bull World Health Organ 2005; 83 (7) 558-559
• 87 Floyd K, Arora VK, Murthy KJ , et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 2006; 84 (6) 437-445
• 88 Pantoja A, Floyd K, Unnikrishnan KP , et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part 1: Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 2009; 13 (6) 698-704
• 89 Pai M, O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008; 29 (5) 560-568
• 90 Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008; 7 (5) 635-650
• 91 Lienhardt C, Raviglione M, Spigelman M , et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl. 02) S241-S249
• 92 Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS ONE 2012; 7 (7) e42479
• 93 Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68 (12) 2240-2246
• 94 Moreno-Serra R, Smith PC. Does progress towards universal health coverage improve population health?. Lancet 2012; 380 (9845) 917-923
• 95 Squire SB, Obasi A, Nhlema-Simwaka B. The Global Plan to Stop TB: a unique opportunity to address poverty and the Millennium Development Goals. Lancet 2006; 367 (9514) 955-957
• 96 Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. A sustainable agenda for tuberculosis control and research. Lancet 2012; 379 (9821) 1077-1078
• 97 World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: WHO; 2007
• 98 Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367 (9514) 952-955